• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4598979)   Today's Articles (2129)   Subscriber (49356)
For: Liang E, Liu WJ, Lohr L, Nguyen V, Lin H, Munson ML, Crans G, Cedarbaum J. P2‐476: A Phase 1, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral daily doses of ELND006 in healthy elderly subjects. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.1347] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Number Cited by Other Article(s)
1
Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease. J Neuroimmunol 2019;326:62-74. [DOI: 10.1016/j.jneuroim.2018.11.010] [Citation(s) in RCA: 107] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Revised: 11/16/2018] [Accepted: 11/18/2018] [Indexed: 12/21/2022]
2
Gullapalli R, Wong A, Brigham E, Kwong G, Wadsworth A, Willits C, Quinn K, Goldbach E, Samant B. Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies. Drug Deliv 2012;19:239-46. [DOI: 10.3109/10717544.2012.691121] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA